title: [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
authors: IGES Institut GmbH, Berlin.
authors: P K
authors: PK
authors: Schädlich
authors: K C
authors: KC
authors: Koltermann
authors: F-W
authors: FW
authors: Dippel
authors: E-G
authors: EG
authors: Hagenmeyer
authors: B
authors: B
authors: Häussler